Frederick L Locke, Tanya Siddiqi, Caron A Jacobson, Armin Ghobadi, Sairah Ahmed, David B Miklos, Miguel-Angel Perales, Javier Munoz, Warren B Fingrut, Martina Pennisi, Jordan Gauthier, Mazyar Shadman, Lohith Gowda, Abu-Sayeef Mirza, Muhammad Bilal Abid, Sanghee Hong, Navneet S Majhail, Mohamed A Kharfan-Dabaja, Arushi Khurana, Talha Badar, Yi Lin, N Nora Bennani, Megan M Herr, Zhen-Huan Hu, Hailin Wang, Anjani Baer, Elande Baro, Harry Miao, Clare Spooner, Hairong Xu, Marcelo C Pasquini
Axicabtagene ciloleucel (axi-cel) is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy approved for treatment of relapsed/refractory (R/R) large B-cell lymphoma (LBCL). Despite extensive data supporting the use of axi-cel in patients with LBCL, outcomes stratified by race and ethnicity groups are limited. Here, we report clinical outcomes with axi-cel in patients with R/R LBCL by race and ethnicity in both real-world and clinical trial settings. In the real-world setting, 1290 patients with R/R LBCL who received axi-cel between 2017-2020 were identified from the Center for International Blood and Marrow Transplant Research database; 106 and 169 patients were included from the ZUMA-1 and ZUMA-7 clinical trials, respectively...
April 18, 2024: Blood